Tirzepatide and Mounjaro represent the latest advancements in diabetes and obesity management, primarily used in the United States. Tirzepatide, marketed under the name Mounjaro, is a novel medication that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
This dual agonist approach is designed to enhance the body’s ability to regulate blood sugar and promote weight loss.
Tirzepatide has been approved by the FDA for the treatment of type 2 diabetes, and it is also being studied for its potential benefits in weight management due to its significant effects on weight reduction in clinical trials.
Mounjaro, as the brand name for tirzepatide, is gaining attention for its effectiveness in treating patients with type 2 diabetes who may also be struggling with obesity.